List of Figures

Sr. No.	Title	Page No.
CHAPTER I	**Introduction**	**1-93**
Figure 1	Clinical types of vitiligo	4
Figure 2	Structure of the skin	6
Figure 3	Different locations of melanocytes in the human body and their functions	8
Figure 4	Production of Eumelanin and Pheomelanin in Melanocytes	10
Figure 5	Description and electron micrographs of the four major stages of eumelanin melanosome maturation within melanocytes and keratinocytes	14
Figure 6	Different hypothesis proposed for vitiligo etiopathogenesis	16
Figure 7	Interplay of oxidative stress, ER stress and inflammatory cytokines leading to melanocyte destruction in vitiligo	45
Figure 8	Structural organization of human PARP-1 (hPARP-1)	47
Figure 9	Developments in the direction of treatment are starting to become public, opening new approaches toward the full understanding of the genetic basis of complex diseases in general and especially of vitiligo.	49
CHAPTER II	**Isolation and Culture Establishment of Primary Normal Human Melanocytes from Epidermal Human Skin**	**94-107**
Figure 1	Establishment of primary cultured human skin melanocytes	100
Figure 2	Confirmation of cultured melanocytes by DOPA staining	101
Figure 3	Differences in cell morphology were observed in the melanocyte culture obtained from different sources	102
CHAPTER III	**To Study the Transcript Levels of the Immune Regulator Genes: *TNFA, IL1A, IL1B, IL4, IL6, IL10, IL1R1, IL1RN* and *IFNG* in Vitiliginous and Control Skin**	**108-130**
Figure 1	Illustration of SNPs association of candidate genes with vitiligo	109
Figure 2	*TNFA* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	114
Figure 3	*IL1A* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	115
Figure 4	*IL1B* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	116
Figure 5	*IL4* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	117
Figure 6	*IL6* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	118
Figure 7	*IL10* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	119
Figure 8	*IFNG* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	120

Figure 9	*IL1R1* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	121
Figure 10	*IL1RN* transcript levels in skin of vitiligo patients (n=12) and controls (n=12)	122
CHAPTER IV	**To Study the Effect of Interleukins on *in vitro* Cultured Melanocyte Cell Death, Expression of Melanin Synthesis Genes and Immunoregulatory Genes.**	**131-172**
Figure 1	H & E stained tissue samples from vitiligo patients and healthy controls	141
Figure 2	Viable epidermal thickness	143
Figure 3	MITF-M expression in control, lesional, non-lesional and peri-lesional skin by Immunofluorescence	144
Figure 4	Densitometric analysis of *in situ* MITF-M levels monitored by immunofluorescence	145
Figure 5	Effect of TNF-α on NHM death	146
Figure 6	Estimation of cellular ROS levels	147
Figure 7	Analysis of Mitochondrial ROS levels	148
Figure 8	Effect of TNF-α on Complex 1 activity	149
Figure 9	Effect of TNF-α on AIF levels	149
Figure 10	Effect of TNF-α on melanogenesis and, *IL6* and *ICAM1* expression	150
Figure 11	Analysis of MITF-M expression by Immunofluorescence upon exogenous stimulation of TNF-α	151
Figure 12	Effect of TNF-α on Autophagy induction	152
Figure 13	Effect of TNF-α on apoptosis of NHM by western blot	153
Figure 14	Effect of IL-6 on melanocyte cell death	154
Figure 15	Effect of IL-6 on *MITF-M, IL6R* and *ICAM1* expression in NHM	155
Figure 16	Analysis of MITF-M levels in NHM upon IL-6 treatment by Immunofluorescence	156
Figure 17	Dose dependent effect of exogenous stimulation of IL-1α on melanocytes cell death	157
Figure 18	Effect of IL-1α on the genes involved in melanogenesis and other immuno-modulatory molecules in NHM	158
Figure 19	Analysis of MITF-M levels in NHM upon IL-1α treatment by Immunofluorescence	159
Figure 20	Effect of IL-10 on cell death of NHM	160
Figure 21	Effect of IL10 on *MITF-M, TYR* and *ICAM1* transcript levels in NHM	161
Figure 22	Analysis of MITF-M levels in NHM upon IL-10 treatment by Immunofluorescence	161
Figure 23	Combinatorial effect of cytokines on NHM viability	162
CHAPTER V	**Effect of Receptor Activation of *TNFR1, IL1R1, IL6R* and *IL10R* upon Treatment with *TNF-α, IL-1α, IL-6 and IL-10* Respectively on *in vitro* Cultured Melanocytes**	**173-195**

Figure 1	Cytokine-receptor interactions	174
Figure 2	TNF signaling	175
Figure 3	The NHM cells were treated with TNF-α (10ng/ml) and then TNFR1 and TNFR2 transcript levels	182
Figure 4	The NHM cells were treated with TNF-α (10ng/ml) and then TNFR1 expression levels were measured after 48 hrs of treatment	183
Figure 5	The NHM cells were treated with TNF-α (10ng/ml) and then TNFR1 expression levels were measured after 48 hrs of treatment	184
Figure 6	IL6 and TNFα induced IL6R gene expression in cultured melanocytes	185
Figure 7	IL6 induced IL6 Receptor activation by confocal microscopy	185
Figure 8	Effect of IL1-α on IL1R1 expression in NHM	186
Figure 9	The NHM cells were treated with IL-1α (10 and 100ng/ml) and then IL1R1 expression levels were measured after 48 hrs of treatment	187
Figure 10	Effect of IL10 on IL10R expression in NHM	188
Figure 11	The NHM cells were treated with IL10 (10ng/ml) and IL10R expression levels were measured after 48 hrs of treatment	189
CHAPTER VI	**To Study the Role of PARP upon H_2O_2 Stimulation of *in vitro* Cultured Melanocytes**	**196-212**
Figure 1	Morphological effect of DHQ on rescue of H_2O_2 induced NHM death	201
Figure 2	Effect of DHQ on rescue of H_2O_2 induced NHM death	202
Figure 3	Analysis of PARylation and PARP1 activation upon DHQ mediated rescue from H_2O_2 induced NHM death	204
Figure 4	Effect of oxidative stress on *MITF-M*, *TYR* and *ICAM-1* mRNA expression	205
Figure 5	Dose dependent effect of H_2O_2 on MITF-M expression in NHM	206
CHAPTER VII-A	***IL1RN* intron 2 VNTR and Vitiligo Susceptibility**	**213-238**
Figure 1	PCR amplification analysis of IL1RN VNTR polymorphism on 3.5% Agarose gel	219
Figure 2	Relative gene expression analysis of *IL1RN* in vitiligo patients and controls	221
Figure 3	Correlation analysis for duration of disease and different genotypes of vitiligo patients	222
CHAPTER VII-B	**Role of *IL10* in Vitiligo Suspectibility**	**239-259**
Figure 1	Representative gel image for the genotyping of IL10-819 C/T SNP using ARMS-PCR	244
Figure 2	Representative gel image for the genotyping of IL10 -592 C/A SNP using PCR-RFLP	246

Figure 3	Representative gel image for the genotyping of IL10 -1082 G/A using PCR-RFLP	247
Figure 4	Haplotype analysis	249
Figure 5	Relative gene expression of IL10 in PBMCs of controls and vitiligo patients	250
Figure 6	Plasma IL10 levels in controls and vitiligo patients	251
Figure 7	Genotype-phenotype correlation of -592 C/A, -819 C/T and -1082 G/A promoter polymorphisms of IL10 transcript and plasma levels in controls and vitiligo patients	252
Figure 8	Effect of IL10 expression on disease progression	253
Figure 9	Effect of IL10 expression on gender biasness	254
Figure 10	Effect of IL10 expression on GV and LV	254
Figure 11	Correlation of IL10 transcript levels with -819 (C/T; rs1800871), -592 (C/A; rs1800872) and -1082 (G/A; rs1800896) promoter polymorphisms with different haplotypes	255
CHAPTER VII-C	**Investigating Association of Promoter Polymorphisms *(-174 G/C)* and *(-572 G/C)* and Transcript levels of Interleukin-6 and Vitiligo in Gujarat**	**260-282**
Figure 1	Genotyping of IL6 gene polymorphisms	266
Figure 2	Analysis of IL-6 transcript levels in controls and vitiligo patients	272
Figure 3	Analysis based on type of the disease	273